DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cow’s Milk Protein Allergy Life Science Investing
SeeThruEquity Issues Update on Q BioMed Highlighting Exclusive Licensing Agreement and Increasing Price Target to $6.00 Biotech Investing
Corvus Pharmaceuticals to Present Data on Lead Oral Checkpoint Inhibitor CPI-444 at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Life Science Investing
Ocera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic Encephalopathy Life Science Investing
